CONCORDBIOConcord Biotech Ltd.

₹1583.7-1.20%

Market Cap

₹16,743.30 Cr

Stock P/E

47.02

ROCE

29.62%

ROE

22.26%

Book Value

₹177.34

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Public

Others

From Last Concall

POSITIVES

•
US FDA approvals for teriflunomide tablets (7 mg and 14 mg) for relapsing MS in the United States, expanding the product portfolio.
•
Global regulatory clearances across major authorities reaffirm quality standards (US FDA, EU GMP, Russian GMP).

NEGATIVES

•
Quarterly results show revenue softness; Q1 FY26 revenues declined 5% YoY to INR 204 crores.
•
API business weakness with 10% YoY decline in revenue; cyclicality/lumpiness impacting API segment.

Peers Summary

Sector Leader

Concord Biotech Ltd. stands out in the Pharmaceuticals & Drugs sector, demonstrating strong profitability metrics and efficient operations despite a unique growth trajectory. While peers exhibit varying strengths, Concord's low debt levels and solid ROE position it favorably, making it a competitive player within its industry.

Key Points

• Concord Biotech Ltd. has the highest ROE (21.88%) among its peers, indicating strong profitability relative to equity.
• The company has a very low debt-equity ratio (0.0041), which enhances its financial stability and reduces risk.
• Concord's revenue growth over three years (154.5%) is remarkable, although it shows no YoY growth, suggesting volatility in its revenue performance.

Top Performers

Concord Biotech Ltd.

Highest ROE (21.88%) and lowest debt-equity ratio (0.0041) indicate strong profitability and low financial risk.

Dr. Reddy's Laboratories Ltd.

Strong growth trajectory with high EPS (68.07) and solid profitability metrics.

Mankind Pharma Ltd.

High revenue growth YoY (18.12%) and solid profitability (ROE 23.15%).

Explore

Watchlists

Command Palette